4-(4-Methylpentyl)oxane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 4-(4-Methylpentyl)oxane
• 英文别名: 4-(4-methylpentyl)oxane
• 化学式: C₁₁H₂₂O
• 分子量: 170.29
• InChiKey: PHJQTQRHXIONAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS
  申请人：Incyte Corporation

  公开号：US20170190689A1

  公开（公告）日：2017-07-06

  The present disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (PI3Kγ) and are useful in the treatment of diseases related to the activity of PI3Kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

  本公开提供了化合物I的化合物，或其药用盐，其调节磷脂酰肌醇3-激酶-γ（PI3Kγ）的活性，并且在治疗与PI3Kγ活性相关的疾病方面具有用途，例如自身免疫疾病、癌症、心血管疾病和神经退行性疾病。
• [EN] ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES<br/>[FR] COMPOSÉS INHIBITEURS DE CANAUX IONIQUES, FORMULATIONS PHARMACEUTIQUES, ET UTILISATIONS
  申请人：AFASCI INC

  公开号：WO2017083867A1

  公开（公告）日：2017-05-18

  The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and / or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.

  本发明主要针对新的化学实体，其主要抑制人类T型钙通道，并差异调节其他关键离子通道，以控制细胞兴奋性，以及参与持续性或慢性疼痛的发展和维持，和/或神经系统疾病的异常神经元活动。这些新颖化合物对治疗和预防这些离子通道参与的神经和精神疾病和疾病具有用处。该发明还涉及包含这些化合物的药物配方以及这些化合物的用途。
• Ion channel inhibitory compounds, pharmaceutical formulations, and uses
  申请人：AFASCI, Inc.

  公开号：US10562857B2

  公开（公告）日：2020-02-18

  The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and/or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.

  本发明针对的新化学实体主要抑制人类 T 型钙通道，并对其他关键离子通道进行不同程度的调节，以控制细胞兴奋性和异常神经元活动，特别是与持续或慢性疼痛和/或神经紊乱的发展和维持有关的异常神经元活动。这些新型化合物可用于治疗和预防涉及这些离子通道的神经和精神疾病。本发明还涉及包含这些化合物的药物制剂以及这些化合物的用途。
• TRICYCLIC DERIVATIVE
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20170273985A1

  公开（公告）日：2017-09-28

  Disclosed are compounds useful as inhibitors of phosphodiesterase 1 (PDE1), compositions thereof, and methods of using the same.
• PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
  申请人：Calico Life Sciences LLC

  公开号：US20200299246A1

  公开（公告）日：2020-09-24

  Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.